Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities

PHASE2TerminatedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 4, 2020

Primary Completion Date

February 22, 2024

Study Completion Date

February 22, 2024

Conditions
Primary Familial Dilated Cardiomyopathy
Interventions
DRUG

danicamtiv

Myosin activator

Trial Locations (19)

15006

Local Institution - 0012, A Coruña

19104

Local Institution - 0001, Philadelphia

20007

Local Institution - 0010, Washington D.C.

28222

Local Institution - 0013, Majadahonda

29425

Local Institution - 0004, Charleston

30120

Local Institution - 0011, El Palmar

33612

Local Institution - 0009, Tampa

38138

Local Institution - 0008, Germantown

43210

Local Institution - 0019, Columbus

55905

Local Institution - 0005, Rochester

69120

Local Institution - 0014, Heidelberg

78705

Local Institution - 0018, Austin

92037

Local Institution - 0007, La Jolla

97080

Local Institution - 0015, Würzburg

60611-5966

Local Institution - 0002, Chicago

02115

Local Institution - 0003, Boston

44195-0001

Local Institution - 0006, Cleveland

EC1A 7BE

Local Institution - 0016, London

UB9 6JH

Local Institution - 0017, Middlesex

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT04572893 - Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities | Biotech Hunter | Biotech Hunter